Search
Now showing items 1-5 of 5
Monoamine oxidase inhibition by indanone and benzoquinone analogues
(North-West University (South Africa) , Potchefstroom Campus, 2015)
Parkinson’s disease (PD) is a neurological disorder of which aging is the greatest risk factor. Over the next fifteen years, the number of persons affected by PD worldwide is expected to increase from 4.6 million to 9.3 ...
Identification of monoamine oxidase inhibitors using a molecular modelling approach
(2014)
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane and is considered to be a target for the treatment of diseases such as Parkinson’s disease and depression. MAO may be classified into two ...
Syntheses of sulfanylphthalimide and xanthine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of adenosine receptors
(North-West University, 2013)
Currently L-DOPA is the drug most commonly used for the treatment of Parkinson’s disease (PD). However, the long-term use of L-DOPA is associated with the development of motor fluctuations and dyskinesias. Treatment mainly ...
Evaluation of selected dye compounds as inhibitors of monoamine oxidase
(North-West University (South-Africa), 2019)
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative diseases that significantly impact the quality of life of patients. The pathology of Parkinson’s disease is characterised by neuronal death of the ...
In silico screening, synthesis and in vitro determination of the biological activities of D-amino acid oxidase inhibitors
(North-West University (South-Africa), 2022)
Schizophrenia is a mental disorder with many clinical and therapeutic challenges. Current therapy is based on outdated pathological theories while most antipschycotic drugs have a significant side effect profile. New ...